07:54 EST Alumis (ALMS) jumps 106% to $17.11 after psoriasis trial hits endpoints
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Alumis Unveils Positive Phase 3 Data for Psoriasis Drug
- Alumis announces Phase 3 trial of envudeucitinib met all primary endpoints
- Alumis Faces Legal Dispute Over Unpaid Budoprutug Milestone
- Alumis Inc.: Validated TYK2 Class, Multiple 2026 Catalysts, and Discounted Valuation Support Buy Rating
- Leerink says Takeda results signal positive readthrough for Alumis